Acurx announces ibezapolstat scientific posters and presentations at clostpath 2023 and idweek 2023 scientific conferences

Three scientific posters highlighting novel anti-virulence pharmacologic properties of oral ibezapolstat for c. difficile infection; effects on toxin production, biofilm and the gut microbiome a podium presentation entitled first of a new class of antibiotics (pol iiic inhibitors) targeting cdc/fda/who priority pathogens; preparing for the next pandemic: antimicrobial resistance in gram-positive bacterial infections ibezapolstat has previously received fda qidp and fast-track designation staten island, n.y.
ACXP Ratings Summary
ACXP Quant Ranking